Houlihan Lokey has now reported its fiscal Q1 results, and the stock is holding the bulk of its pre-earnings gains — the question shifts from what traders feared to what the market is actually pricing in.
The earnings reaction was constructive. The most recent print on July 27 produced a 3.7% next-day gain, reversing the -3.0% move seen after the prior quarter in May. That back-to-back contrast matters: the May print triggered mild follow-through selling over the subsequent week, whereas this quarter the stock closed at $145.47, up 3% on the day and 4% on the week. The defensive caution that had been building in options — flagged ahead of the print — appears to have been the wrong call.
Options positioning has shifted since the earnings preview. The put/call ratio remains above its 20-day average at 0.30 versus a mean of 0.20, still roughly 1.3 standard deviations elevated, but the ratio has been stable for several sessions rather than climbing. That suggests the hedging demand that built into the print has largely stayed in place rather than unwinding — noteworthy, given the stock has not sold off. The lending market continues to offer no signal of bearish conviction: borrow availability is extraordinarily loose at roughly 6,200%, borrowing costs are negligible at 0.38%, and short interest has barely moved, edging up less than 1% on the week to 3.3% of the free float. Nothing in positioning looks crowded on the short side.
The Street remains broadly constructive but has been trimming numbers. Morgan Stanley held its Overweight but lowered its target to $187 from $193 earlier this month, and Keefe Bruyette & Woods kept its Outperform while cutting to $160 from $172 — moves that keep ratings intact but acknowledge the stock has underperformed year-to-date targets set earlier in 2026. The consensus mean of $169.75 still implies around 17% upside from current levels. Valuation multiples have drifted modestly: the P/E has expanded to 16.6x on a 30-day basis, up roughly 1.5 turns, while price-to-book is running at 3.6x. The forward EPS growth score ranks in the 81st percentile, and the analyst recommendation divergence factor scores in the 90th — meaning HLI screens as a name where bulls have meaningfully more conviction than the consensus might suggest.
Among peers, the week told a mixed story. SF was the standout, up 9% on the week, while PJT added nearly 4% and APAM rose 4.3%. EVR was flat and LAZ fell 1.7%. HLI's 4% weekly gain sits comfortably in the upper half of the peer group — not a breakout, but a genuine outperformer relative to the flat-to-negative names.
What to watch now is whether institutional holders add to positions following a clean earnings print: BlackRock reported adding 105,000 shares through June 30, while insiders — including the CEO, CFO, and multiple co-chairs — collectively sold over $8.5 million of stock in May at prices around $150, slightly above where the stock trades today.
See the live data behind this article on ORTEX.
Open HLI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
